Skip to main content

Changes Come to Genzyme

Henri Termeer, the CEO of Genzyme, told the Wall Street Journal's Health Blog last week that he was considering selling some of the company's non-essential business, and this week the company said which ones were for sale: its genetic testing, diagnostics, and pharmaceutical intermediates businesses. "As we evaluated our company to create a mix of businesses that will deliver sustainable growth and stronger returns on invested capital, it became clear that these businesses do not fit within this strategy," Termeer says in a statement, according to Dow Jones Newswires. The Health Blog adds that when it "chatted with Termeer last week, he was full of praise from one of the activist investors who's been pressing for change at the company — Ralph Whitworth" though Termeer "had fewer kind words for Carl Icahn."

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.